+91 7986995600
seclislabs@gmail.com
Contact Us
Home › INJECTABLES/ IV/INFUSION › BrewXONE™ TZ 1.125
INJECTABLES/ IV/INFUSION

BrewXONEâ„¢ TZ 1.125

Ceftriaxone 1gm + Tazobactum 125mg

Dosage Form Dry Injection
Packing 1 Vial
MRP ₹195
Prescribed By General Medicine, Infectious Disease, Pulmonology

Quick Facts

Form Dry Injection
Pack 1 Vial
MRP Rs.195
Prescribed By General Medicine, Infectious Disease, Pulmonology

Key Benefits

01
Tazobactam is a more potent beta-lactamase inhibitor than Sulbactam.
02
Effective against ESBL-producing organisms.
03
Combination extends Ceftriaxone's spectrum significantly.
04
Useful for resistant infections in hospital settings.

Mechanism of Action

Ceftriaxone provides broad-spectrum cephalosporin activity. Tazobactam is a potent beta-lactamase inhibitor that protects Ceftriaxone from beta-lactamase-producing resistant bacteria, including ESBL-producing organisms.

Indications

ESBL-producing bacterial infections, resistant hospital-acquired infections, serious polymicrobial infections.

Dosage & Administration

Take as prescribed by your doctor or healthcare professional. Do not self-medicate.

Why BrewXONEâ„¢ TZ 1.125?

BrewXONE TZ 1.125 uses the more potent Tazobactam inhibitor alongside Ceftriaxone — providing superior coverage against ESBL-producing and other resistant organisms compared to Sulbactam combinations.

Interested in franchising BrewXONEâ„¢ TZ 1.125?

Get exclusive monopoly rights in your territory. WHO-GMP certified. Pan India coverage with dedicated support.

📢

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.

Scroll to Top